Euroopa Liit - rumeenia - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresoare - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - escitalopramum - compr. film. - 5mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - escitalopramum - compr. film. - 10mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - escitalopramum - compr. film. - 15mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - escitalopramum - compr. film. - 20mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresoare - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 și 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 și 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - erlotinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - erlotinibum - compr. film. - 150mg - alte antineoplazice inhibitori de protein-kinaza

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - erlotinibum - compr. film. - 25mg - alte antineoplazice inhibitori de protein-kinaza

Rumeenia - rumeenia - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

krka, d.d., novo mesto - slovenia - acid acetylsalicylicum - compr. gastrorez. - 75mg - antitrombotice antiagregante plachetare